ADORA3 and asthma: It is known that the selective agonism of A3 adenosine receptors is associated with anticancer [20], cardioprotective [21,22] and cerebroprotective activity [23,24] while the selective antagonists [25] for A3 adenosine receptors are of potential clinical use for combating inflammation and asthma.